Unipolar depression is a major public health problem and will be the second most prevalent cause of illness-induced disability by the year 2020 according to the World Health Organization. There are several antidepressant drugs that are effective and relatively safe, but they all require a long latency (usually 3-4 weeks) to improve depressive symptoms. This latency seriously complicates the management of severely depressed patients, who are at high risk for suicide during the early phases of treatment. Paradoxically, suicide attempts may even increase during the first days of antidepressant medication because of the shorter latency of drug-induced psychomotor activation. Fast-active drugs or adjunctive drugs that shorten the clinical latency of classical antidepressants will provide a major breakthrough in the treatment of depression. Recent evidence suggests that glutamate receptors are potential targets for antidepressant drugs. 1 These receptors are subdivided into two major classes: (i) ionotropic glutamate receptors (i.e. alphaamino-3-hydroxy-5-methyl-4-isoxazole propionate, N-Methyl-D-aspartate (NMDA) and kainate receptors), which are ligand-gated ion channels; and (ii) metabotropic glutamate (mGlu) receptors, which are coupled to G proteins. NMDA receptor antagonists produce beneficial effects in animal models of depression, [2] [3] [4] but their potential use in humans is limited by their strong impact on excitatory synaptic transmission, which results in serious adverse effects, such as sedation, ataxia and impairment of learning and memory. 5 Drugs acting at mGlu receptors should offer a better profile of tolerability because these receptors 'modulate' rather than mediate synaptic transmission in the central nervous system. 6,7 mGlu receptors form a family of eight subtypes subdivided into three groups on the basis of their amino-acid sequence, pharmacological profile and transduction mechanisms. Group-I mGlu receptors (mGlu1 and mGlu5 receptors) are coupled to Gq, and their activation stimulates polyphosphoinositide (PI) hydrolysis leading to mobilization of intracellular Ca 2 þ and activation of protein kinase C. Group-II (mGlu2 and mGlu3) and group-III (mGlu4, mGlu6, mGlu7 and mGlu8) receptors are all coupled to Gi/o proteins. Their activation inhibits cAMP formation and indirectly affects synaptic transmission and neurotransmitter release by modulating membrane Ca 2 þ and K þ channels. 8 Subtype-selective ligands are now available that either bind to the glutamate-binding domain of mGlu receptors or interact with an allosteric site acting as receptor enhancers or negative modulators. 9 Drugs that inhibit group-I mGlu receptors (particularly the mGlu5 receptor antagonists, 2-methyl-6-(phenylethynyl)-pyridine and ((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine), inhibit group-II mGlu receptors (3-(3,4-dichloro-benzyloxy)-2-amino-6-fluorobicyclo(hexane-2,6-dicarboxylic acid 6-heptyl ester and 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionate (LY341495)) or activate group-III receptors (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid, (RS)-4-phosphonophenylglycine and (N-phenyl-7-(hydroxyimino)cyclopropane(b)chromen-1-acarboxamide) are effective in animal models of depression, and, in same cases, produce behavioral effects that are consistent with an antidepressant activity. 10, 11 We have focused on how mGlu receptors affect neuroadaptive changes induced by classical antidepressants. Initially, we found that a 21-day treatment with the tricyclic antidepressant imipiramine increases the expression of mGlu2/3 receptors in brain regions that are implicated in the pathophysiology of depression, such as the hippocampus and nucleus accumbens. One of the established functions of these receptors, that is their synergistic activity with mGlu1/5 receptors in stimulating PI hydrolysis, was enhanced in hippocampal slices isolated from animals treated with imipramine. 12 We reasoned that the upregulation of mGlu2/3 receptors could contribute to the overall process of neuroadaptation to antidepressants, and addressed this issue by monitoring the downregulation of b-adrenergic receptors in mice treated with imipramine for up to 21 days. Interestingly, the latency required for the downregulation of b-adrenergic receptors in the hippocampus was shortened from 21 to 14 days when imipramine was combined either with low doses of the mGlu2/3 receptor agonist, (À)-2-oxa-4-aminobicy-clo(exhane-4,6-dicarboxylic acid (LY379268) (0.5 mg/kg, intra peritoneally (i.p.)), or with the preferential mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.). 13 We interpreted these findings by speculating that low doses of LY379268 activated a subset of mGlu2 or mGlu3 receptors producing functional effects similar to those resulting from an overall receptor blockade with LY341495, or, alternatively, that the antagonist LY341495 could recruit additional receptor subtypes. 13 Currently, we are examining the combination between LY379268 and antidepressant drugs both in vitro and in vivo. We are using cultured cerebellar granule cell neuroprogenitors as an in vitro model of antidepressant-induced neurogenesis 14 (see brief methods in the legend in Figure 1 ). In these cultures, low concentrations of LY379268 (1 nM) acted synergistically with the selective serotonin reuptake inhibitor, fluoxetine, in enhancing both cell proliferation and neurogenesis (Figure 1a and b) . In vivo experiments were carried out using Flinders-sensitive line (FSL) rats, which show spontaneous 'depressive' symptoms, including an increased immobility time in the forced swim test. 15 The exaggerated immobility is reduced by a chronic, but not subchronic, treatment with antidepressants. 16 A 3-day treatment of FSL rats with either chlorimipramine (10 mg/kg, i.p.) or LY379268 (0.5 mg/kg, i.p., once daily) produced only small effects in the forced swim test. However, a combination of the two drugs for 3 days substantially reduced the immobility time (Figure 1c) , supporting the hypothesis that antidepressants have a shorter latency of action if mGlu2/3 receptors are activated at the same time.
Taken together, these data raise the attractive possibility that mGlu2/3 receptor ligands (either low doses of agonists or antagonists) may be used as adjunctive drugs to shorten the latency of antidepressant medication, provided that these drugs will also show a good profile of safety and tolerability, as can be predicted from animal studies. Figure 1 Fluoxetine combined with metabotropic glutamate 2/3 receptor agonist, LY379268, increases cell proliferation (a) and neurogenesis (b) in cultured cerebellar granule neuroprecursors. Primary cultures of rat cerebellar granule cells were prepared from 6-7-day-old rat pups and grown in serum-free neurobasal medium, supplemented with 10 ng/ml EGF and 20 ng/ml bFGF (Zusso et al., 2004) . Ten days after plating, putative granule cell neuroprogenitors, identified as round-shaped cells, were isolated, replated and treated for 72 h with fluoxetine (10 nM), LY379268 (1 nM), or the two drugs in combination. Cell proliferation was assessed by counting the cells immunoreactive for 5-bromo-2 0 -deoxyuridine (BrdU, applied 24 h before at the concentration of 10 mM). For assessment of neurogenesis, cells were re-plated in poly-L-lysine in medium deprived of mitogens and containing 10% fetal calf serum. Neurons were identified by the expression of b-III-tubulin using TuJ1 antibodies (1:100). Values were counted in three random microscopic fields/per dish and are means7s.e.m. of 4-6 determinations. *P < 0.05 vs controls (one-way ANOVA þ Fisher's PLSD). In (c), a 3-day of treatment with chlorimipramine combined with LY379268 induces a substantial decrease of total immobility time in forced swim test in FSL rats. FSL rats were treated with saline, chlorimipramine 10 mg/kg i.p., LY379268 0.5 mg/kg i.p., or the two drugs in combination once daily for 3 days. A standard 5-min test was performed 24 h after the last injection. Time values are expressed as seconds, and are means7s.e.m. of six animals per group. *P < 0.05 (one-way ANOVA þ Fisher's PLSD) vs rats treated with saline.
